Skip to main content
VCbacked
Log inGet Started

Ratio Therapeutics

Boston, United States

Ratio Therapeutics is a clinical phase pharmaceutical company that develops radiopharmaceuticals for solid tumors.

$50.0M raised
Jan 2024
Series B
BiopharmaBiotechnologyLife ScienceMedicalPharmaceutical

Top Investors

Bristol-Myers SquibbCornell UniversityThe Pags GroupSchusterman Family InvestmentsDuquesne Capital Management

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Ratio Therapeutics

How much funding has Ratio Therapeutics raised?
Ratio Therapeutics has raised $50.0M in total funding. The most recent round was Series B. The last funding was announced in January 2024.
Who are Ratio Therapeutics's investors?
Ratio Therapeutics's investors include Bristol-Myers Squibb, Cornell University, The Pags Group, Schusterman Family Investments, Duquesne Capital Management.
Where is Ratio Therapeutics headquartered?
Ratio Therapeutics is headquartered in Boston, United States.
What does Ratio Therapeutics do?
Ratio Therapeutics is a clinical phase pharmaceutical company that develops radiopharmaceuticals for solid tumors.
What stage is Ratio Therapeutics at?
Ratio Therapeutics is at the Series B stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Ratio Therapeutics — Funding & Investors." VCBacked, January 17, 2024, https://www.vcbacked.co/company/ratio-therapeutics. Accessed June 3, 2026.
APA
VCBacked. (2024). Ratio Therapeutics — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/ratio-therapeutics
Wikipedia (cite web)
{{cite web |title=Ratio Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ratio-therapeutics |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biopharma

View all
ParcelBio
San Francisco$13.2M
Modicus Prime
Austin
Latus Bio
Philadelphia
Ocugen
Malvern
Ember LifeSciences
Los Angeles$16.5M
ClearNote Health
San Diego